デフォルト表紙
市場調査レポート
商品コード
1478594

関節リウマチ治療薬の市場規模 - 薬剤クラス・投与経路・販売チャネル・流通チャネル別 - 地域別展望・競合戦略・セグメント予測 (~2033年)

Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 234 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
関節リウマチ治療薬の市場規模 - 薬剤クラス・投与経路・販売チャネル・流通チャネル別 - 地域別展望・競合戦略・セグメント予測 (~2033年)
出版日: 2024年04月19日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 234 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の関節リウマチ治療薬の市場規模は、2033年にかけて3.8%のCAGRで推移し、787億1,842万の規模に成長すると予測されています。

関節リウマチは、身体の免疫システムが関節を含む自身の組織を攻撃する自己免疫疾患です。関節リウマチの治療に使用される薬は抗リウマチ薬として知られています。すべての年齢層がこの病気に罹患しますが、高齢者が最も罹患しやすくなっています。関節リウマチの症状には、関節の腫れ、こわばり、痛み、不快感などがあります。関節リウマチは現在、治療法が確立されていません。

2020年1月30日、世界保健機関 (WHO) はCOVID-19を世界の公衆衛生上の緊急事態とみなしました。COVID-19は世界約210カ国に影響を及ぼしました。Lancet Rheumatology 2020によると、関節リウマチ患者によるCOVID-19感染は、重篤な症状に至る可能性が高いです。ヒドロキシクロロキンなどの特定のDMARDsは、関節リウマチの治療にしばしば使用されるだけでなく、COVID-19治療薬の可能性も研究されています。

当レポートでは、世界の関節リウマチ治療薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因・抑制要因・機会・課題の分析
  • COVID-19の市場への影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 競合情勢

  • 製造拠点の分布・販売エリア・製品タイプ
  • M&A・提携・製品発売・協力

第7章 世界の関節リウマチ治療薬市場:薬剤クラス別

  • 世界市場の規模・シェア・予測
  • 疾患修飾性抗リウマチ薬 (DMARD)
  • 非ステロイド性抗炎症薬 (NSAID)
  • コルチコステロイド
  • 尿酸薬
  • その他

第8章 世界の関節リウマチ治療薬市場:投与経路別

  • 世界市場の規模・シェア・予測
  • 経口
  • 非経口

第9章 世界の関節リウマチ治療薬市場:販売チャネル別

  • 世界市場の規模・シェア・予測
  • 処方薬
  • OTC薬

第10章 世界の関節リウマチ治療薬市場:流通チャネル別

  • 世界市場の規模・シェア・予測
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 世界の関節リウマチ治療薬市場の予測

  • 市場規模・市場シェア

第12章 世界の関節リウマチ治療薬市場:地域別

  • 市場規模・市場シェアの推移・予測
  • アジア太平洋
  • 欧州
  • 中東・アフリカ
  • 北米
  • ラテンアメリカ

第13章 企業プロファイル

  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • その他

第14章 略語一覧

第15章 参考リンク

第16章 総論

第17章 調査範囲

目次
Product Code: PHAR2406

Rheumatoid Arthritis Drugs Market Introduction and Overview

According to SPER market research, Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033 state that the Global Rheumatoid Arthritis Drugs Market is predicted to reach 78718.42 million by 2033 with a CAGR of 3.8%.

Rheumatoid arthritis is an autoimmune disease that results in the body's immune system attacking its own tissues, including joints. This leads to edema and painful joint stiffness. A medication used to treat rheumatoid arthritis is known as an anti-rheumatic medication. All ages are affected by this ailment, albeit the elderly are most susceptible to it. Rheumatoid arthritis symptoms include swelling, stiffness, pain, and discomfort in the joints. Rheumatoid arthritis currently has no recognized treatment.

On January 30, 2020, the World Health Organization (WHO) deemed the COVID-19 pandemic a global public health emergency. Globally, COVID-19 has had an impact on around 210 countries. Patients with rheumatoid arthritis who also have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, such hydroxychloroquine, are being studied as possible COVID-19 therapies in addition to being often used to treat rheumatoid arthritis.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Segmentation

By Drug Class Type: Based on the Drug Class Type, Global Rheumatoid Arthritis Drugs Market is segmented as, Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others.

By Route of Administration: Based on the Route of Administration, Global Rheumatoid Arthritis Drugs Market is segmented as; Oral, Parenteral.

By Sales Channel: Based on the Sales Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Prescription-based Drugs, Over-the-counter Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market

7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033

  • 7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
  • 7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
  • 7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • 7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.5. Corticosteroids
  • 7.6. Uric Acid Drugs
  • 7.7. Others

8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033

  • 8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
  • 8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
  • 8.3. Oral
  • 8.4. Parenteral

9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033

  • 9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
  • 9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
  • 9.3. Prescription-based Drugs
  • 9.4. Over-the-counter Drugs

10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033

  • 10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 10.3. Hospital Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Online Pharmacy

11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)

  • 11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share

12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)

  • 12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
  • 12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Qatar
    • 12.5.4. South Africa
    • 12.5.5. Egypt
    • 12.5.6. Morocco
    • 12.5.7. Nigeria
    • 12.5.8. Rest of Middle-East and Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profile

  • 13.1. AbbVie Inc.
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Johnson & Johnson Innovative Medicine
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Amgen Inc.
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Pfizer Inc.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. Novartis AG
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Sanofi S.A.
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. F. Hoffmann-La Roche Ltd.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Merck & Co., Inc.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Bristol-Myers Squibb Company
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Eli Lilly and Company
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope